BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...
The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward tech innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback